STOCK TITAN

[424B2] Royal Bank of Canada Prospectus Supplement

Filing Impact
(No impact)
Filing Sentiment
(Neutral)
Form Type
424B2
Rhea-AI Filing Summary

Venus Concept Inc. (NASDAQ: VERO) has completed a series of related financing amendments designed to ease near-term liquidity pressure and realign its capital structure.

On 30 June 2025 the Company executed an Exchange Agreement with its senior lender Madryn Health Partners. Two existing secured subordinated convertible notes with aggregate principal of $17.0 million were exchanged for (i) new promissory notes totalling $11.1 million and (ii) 325,651 shares of newly issued Series Y Convertible Preferred Stock priced at $19.96 per share. Each preferred share converts into 9.0909 common shares, implying potential issuance of roughly 3.0 million additional common shares once conversion limits are lifted.

The transaction immediately reduces debt principal by about $5.9 million, shifts a portion of lender exposure into equity and carries no registration requirement under Section 3(a)(9). A Third Amended & Restated Registration Rights Agreement obligates the Company to file a shelf registration for the conversion shares within 60 days after all preferred shares convert.

Concurrently, the Company and Madryn executed several consent and amendment agreements: (1) waiver of minimum liquidity covenants on both the Main Street Priority Loan and the new notes through 31 July 2025, (2) permission to apply the 8 July 2025 interest payment to principal, and (3) a sixteenth amendment to the Bridge Loan extending maturity by one month to 31 July 2025.

To support the larger preferred issuance, Venus filed a Certificate of Amendment increasing authorized Series Y shares from 1.2 million to 1.5 million. A shareholder vote will be sought to remove Nasdaq-related conversion limits.

Overall, the package provides short-term covenant relief and modest debt reduction but adds potential equity dilution and highlights ongoing liquidity constraints, with several key maturities now deferred only to late July 2025.

Venus Concept Inc. (NASDAQ: VERO) ha completato una serie di modifiche finanziarie correlate volte ad alleviare la pressione sulla liquidità a breve termine e riallineare la sua struttura del capitale.

Il 30 giugno 2025 la Società ha stipulato un Accordo di Scambio con il suo principale finanziatore Madryn Health Partners. Due note convertibili subordinate garantite esistenti, con un valore nominale complessivo di 17,0 milioni di dollari, sono state scambiate con (i) nuove cambiali per un totale di 11,1 milioni di dollari e (ii) 325.651 azioni di nuova emissione della Serie Y Preferred Convertible valutate a 19,96 dollari per azione. Ogni azione preferenziale si converte in 9,0909 azioni ordinarie, implicando un’emissione potenziale di circa 3,0 milioni di azioni ordinarie aggiuntive una volta rimossi i limiti di conversione.

L’operazione riduce immediatamente il capitale del debito di circa 5,9 milioni di dollari, sposta una parte dell’esposizione del finanziatore in capitale proprio e non richiede registrazione ai sensi della Sezione 3(a)(9). Un Terzo Accordo Emendato e Rifirmato sui Diritti di Registrazione obbliga la Società a presentare una registrazione a scaffale per le azioni di conversione entro 60 giorni dalla conversione di tutte le azioni preferenziali.

Parallelamente, la Società e Madryn hanno firmato diversi accordi di consenso e modifica: (1) rinuncia ai covenant di liquidità minima sia per il Main Street Priority Loan che per le nuove cambiali fino al 31 luglio 2025, (2) autorizzazione ad applicare il pagamento degli interessi del 8 luglio 2025 al capitale, e (3) una diciassettesima modifica al Bridge Loan che estende la scadenza di un mese fino al 31 luglio 2025.

Per supportare l’emissione maggiore delle azioni preferenziali, Venus ha depositato un Certificato di Modifica che aumenta le azioni autorizzate della Serie Y da 1,2 milioni a 1,5 milioni. Sarà richiesto un voto degli azionisti per rimuovere i limiti di conversione legati al Nasdaq.

In sintesi, il pacchetto offre un sollievo temporaneo dai covenant e una modesta riduzione del debito, ma comporta una potenziale diluizione azionaria e mette in evidenza le persistenti restrizioni di liquidità, con diverse scadenze chiave ora posticipate solo a fine luglio 2025.

Venus Concept Inc. (NASDAQ: VERO) ha completado una serie de enmiendas financieras relacionadas diseñadas para aliviar la presión de liquidez a corto plazo y realinear su estructura de capital.

El 30 de junio de 2025, la Compañía ejecutó un Acuerdo de Intercambio con su prestamista principal Madryn Health Partners. Dos pagarés convertibles subordinados garantizados existentes, con un principal agregado de 17,0 millones de dólares, fueron intercambiados por (i) nuevos pagarés por un total de 11,1 millones de dólares y (ii) 325,651 acciones recién emitidas de la Serie Y Convertible Preferred Stock valoradas en 19,96 dólares por acción. Cada acción preferente se convierte en 9,0909 acciones ordinarias, lo que implica una emisión potencial de aproximadamente 3,0 millones de acciones ordinarias adicionales una vez que se levanten los límites de conversión.

La transacción reduce inmediatamente el principal de la deuda en aproximadamente 5,9 millones de dólares, convierte una parte de la exposición del prestamista en capital y no requiere registro bajo la Sección 3(a)(9). Un Tercer Acuerdo Enmendado y Restablecido de Derechos de Registro obliga a la Compañía a presentar un registro en estantería para las acciones de conversión dentro de los 60 días posteriores a la conversión de todas las acciones preferentes.

Simultáneamente, la Compañía y Madryn ejecutaron varios acuerdos de consentimiento y enmienda: (1) renuncia a los convenios de liquidez mínima tanto en el Préstamo Prioritario Main Street como en los nuevos pagarés hasta el 31 de julio de 2025, (2) permiso para aplicar el pago de intereses del 8 de julio de 2025 al principal, y (3) una decimosexta enmienda al Préstamo Puente que extiende el vencimiento un mes hasta el 31 de julio de 2025.

Para apoyar la mayor emisión preferente, Venus presentó un Certificado de Enmienda que incrementa las acciones autorizadas de la Serie Y de 1,2 millones a 1,5 millones. Se buscará una votación de accionistas para eliminar los límites de conversión relacionados con Nasdaq.

En conjunto, el paquete proporciona alivio temporal de convenios y una reducción modesta de la deuda, pero añade una posible dilución de capital y destaca las continuas restricciones de liquidez, con varios vencimientos clave ahora aplazados solo hasta finales de julio de 2025.

Venus Concept Inc. (NASDAQ: VERO)는 단기 유동성 압박을 완화하고 자본 구조를 재조정하기 위해 일련의 관련 금융 수정 사항을 완료했습니다.

2025년 6월 30일, 회사는 주요 대출기관인 Madryn Health Partners와 교환 계약을 체결했습니다. 총 원금 1,700만 달러의 기존 담보 하위 전환사채 두 건이 (i) 총 1,110만 달러의 새로운 약속어음과 (ii) 주당 19.96달러로 평가된 신규 발행된 시리즈 Y 전환 우선주 325,651주로 교환되었습니다. 각 우선주는 9.0909주의 보통주로 전환되며, 전환 제한이 해제되면 약 300만 주의 추가 보통주가 발행될 수 있습니다.

이번 거래로 부채 원금이 약 590만 달러 감소하고, 대출자의 일부 노출이 주식으로 전환되며, 섹션 3(a)(9)에 따른 등록 요건이 없습니다. 제3차 수정 및 재작성된 등록 권리 계약에 따라 회사는 모든 우선주가 전환된 후 60일 이내에 전환주에 대한 선반 등록을 제출해야 합니다.

동시에 회사와 Madryn은 여러 동의 및 수정 계약을 체결했습니다: (1) 2025년 7월 31일까지 Main Street 우선 대출과 신규 약속어음에 대한 최소 유동성 계약 위반 면제, (2) 2025년 7월 8일 이자 지급액을 원금에 적용하는 허가, (3) 만기를 한 달 연장하여 2025년 7월 31일까지 연장하는 16차 브리지 론 수정.

더 큰 우선주 발행을 지원하기 위해 Venus는 시리즈 Y 승인 주식 수를 120만 주에서 150만 주로 증가하는 수정 증명서를 제출했습니다. Nasdaq 관련 전환 제한을 해제하기 위한 주주 투표가 진행될 예정입니다.

전반적으로 이 패키지는 단기 계약 완화와 적당한 부채 감축을 제공하지만, 잠재적인 주식 희석을 추가하며 지속되는 유동성 제약을 강조합니다. 여러 주요 만기가 이제 2025년 7월 말로 연기되었습니다.

Venus Concept Inc. (NASDAQ : VERO) a finalisé une série d'amendements financiers liés visant à alléger la pression sur la liquidité à court terme et à réaligner sa structure de capital.

Le 30 juin 2025, la Société a conclu un Contrat d'Échange avec son prêteur principal Madryn Health Partners. Deux billets convertibles subordonnés garantis existants, d'un principal total de 17,0 millions de dollars, ont été échangés contre (i) de nouveaux billets à ordre totalisant 11,1 millions de dollars et (ii) 325 651 actions nouvellement émises de Série Y Preferred Convertible au prix de 19,96 dollars par action. Chaque action privilégiée se convertit en 9,0909 actions ordinaires, ce qui implique une émission potentielle d'environ 3,0 millions d'actions ordinaires supplémentaires une fois les limites de conversion levées.

La transaction réduit immédiatement le principal de la dette d'environ 5,9 millions de dollars, convertit une partie de l'exposition du prêteur en capitaux propres et ne nécessite pas d'enregistrement en vertu de la Section 3(a)(9). Un troisième accord modifié et restitué sur les droits d'enregistrement oblige la Société à déposer un enregistrement en étagère pour les actions de conversion dans les 60 jours suivant la conversion de toutes les actions privilégiées.

Parallèlement, la Société et Madryn ont conclu plusieurs accords de consentement et d'amendement : (1) renonciation aux engagements de liquidité minimale sur le prêt prioritaire Main Street et les nouveaux billets jusqu'au 31 juillet 2025, (2) autorisation d'appliquer le paiement des intérêts du 8 juillet 2025 au principal, et (3) une seizième modification du prêt relais prolongeant l'échéance d'un mois jusqu'au 31 juillet 2025.

Pour soutenir la plus grande émission d'actions privilégiées, Venus a déposé un certificat de modification augmentant les actions autorisées de la Série Y de 1,2 million à 1,5 million. Un vote des actionnaires sera sollicité pour supprimer les limites de conversion liées au Nasdaq.

Dans l'ensemble, ce paquet offre un allégement temporaire des engagements et une réduction modeste de la dette, mais entraîne une dilution potentielle des actions et souligne les contraintes de liquidité persistantes, plusieurs échéances clés étant désormais reportées à fin juillet 2025.

Venus Concept Inc. (NASDAQ: VERO) hat eine Reihe von damit verbundenen Finanzierungsänderungen abgeschlossen, die darauf abzielen, den kurzfristigen Liquiditätsdruck zu verringern und die Kapitalstruktur neu auszurichten.

Am 30. Juni 2025 schloss das Unternehmen eine Tauschvereinbarung mit seinem Hauptkreditgeber Madryn Health Partners ab. Zwei bestehende besicherte nachrangige wandelbare Schuldverschreibungen mit einem Gesamtnennwert von 17,0 Millionen US-Dollar wurden gegen (i) neue Schuldscheine mit einem Gesamtwert von 11,1 Millionen US-Dollar und (ii) 325.651 neu ausgegebene Aktien der Serie Y Wandelvorzugsaktien zum Preis von 19,96 US-Dollar pro Aktie getauscht. Jede Vorzugsaktie wandelt sich in 9,0909 Stammaktien um, was eine potenzielle Ausgabe von etwa 3,0 Millionen zusätzlichen Stammaktien impliziert, sobald die Umwandlungsbeschränkungen aufgehoben sind.

Die Transaktion reduziert sofort den Schuldenkapitalbetrag um etwa 5,9 Millionen US-Dollar, verlagert einen Teil der Kreditgeberexposition in Eigenkapital und unterliegt keiner Registrierungspflicht gemäß Abschnitt 3(a)(9). Ein drittes geändertes und neu gefasstes Registrierungsrechtsabkommen verpflichtet das Unternehmen, innerhalb von 60 Tagen nach Umwandlung aller Vorzugsaktien eine Shelf-Registrierung für die Umwandlungsaktien einzureichen.

Gleichzeitig schlossen das Unternehmen und Madryn mehrere Zustimmungs- und Änderungsvereinbarungen ab: (1) Verzicht auf Mindestliquiditätsklauseln sowohl für den Main Street Priority Loan als auch für die neuen Schuldscheine bis zum 31. Juli 2025, (2) Erlaubnis, die Zinszahlung am 8. Juli 2025 auf das Kapital anzurechnen, und (3) eine sechzehnte Änderung des Bridge Loans, die die Fälligkeit um einen Monat bis zum 31. Juli 2025 verlängert.

Zur Unterstützung der größeren Vorzugsausgabe reichte Venus eine Änderungsurkunde ein, die die genehmigten Aktien der Serie Y von 1,2 Millionen auf 1,5 Millionen erhöht. Eine Aktionärsabstimmung wird angestrebt, um die Nasdaq-bezogenen Umwandlungsbeschränkungen aufzuheben.

Insgesamt bietet das Paket kurzfristige Erleichterungen bei den Auflagen und eine moderate Schuldenreduzierung, führt jedoch zu potenzieller Aktienverwässerung und unterstreicht anhaltende Liquiditätsengpässe, wobei mehrere wichtige Fälligkeiten nun erst Ende Juli 2025 anstehen.

Positive
  • Debt principal reduced by approximately $5.9 million, lowering cash interest requirements.
  • Minimum liquidity covenants waived across multiple facilities until 31 July 2025, providing short-term breathing room.
  • Maturity of the bridge loan extended by one month, avoiding an immediate refinancing cliff.
  • Lender converted part of its claim into equity, signalling continued support and aligning incentives.
Negative
  • Series Y Preferred converts into ~3 million common shares, creating significant potential dilution for existing shareholders.
  • Covenant relief and maturity extension last only until 31 July 2025, implying ongoing liquidity stress.
  • All securities issued are unregistered, limiting immediate market liquidity for the new equity.
  • The transactions concentrate further control with a single lender, potentially reducing financing flexibility.

Insights

TL;DR – Debt principal cut by $5.9 m and covenants waived, but dilution and July maturity still loom.

The exchange lowers secured note principal from $17.0 m to $11.1 m, trimming quarterly interest expense and modestly improving leverage. Converting part of Madryn’s claim into preferred equity aligns lender incentives with equity holders and removes near-term cash interest on that piece. However, Series Y converts into ~3 m common shares—about 15-20 % of the current float—setting up meaningful dilution once shareholder approval removes Nasdaq limits. Covenant waivers and a one-month bridge-loan extension underscore tight liquidity; management has until 31 July 2025 to secure longer-term financing or restructure further. Net impact is cautiously positive for solvency but neutral-to-negative for existing equity holders due to dilution risk.

TL;DR – Classic liability-management exchange; improves balance-sheet optics but only buys 30 days of runway.

This transaction swaps subordinated debt into a hybrid instrument, lowering secured debt stack and increasing equity cushion for senior creditors. The use of Section 3(a)(9) avoids registration and speeds execution. Waiving liquidity covenants and redirecting July interest to principal conserves roughly $0.3-0.4 m cash. Yet the short extension of the bridge facility and continued reliance on the same lender indicate limited alternative capital sources. Absent a broader refinancing before 31 July, default risk persists. Investor takeaway: incremental, not transformational.

Venus Concept Inc. (NASDAQ: VERO) ha completato una serie di modifiche finanziarie correlate volte ad alleviare la pressione sulla liquidità a breve termine e riallineare la sua struttura del capitale.

Il 30 giugno 2025 la Società ha stipulato un Accordo di Scambio con il suo principale finanziatore Madryn Health Partners. Due note convertibili subordinate garantite esistenti, con un valore nominale complessivo di 17,0 milioni di dollari, sono state scambiate con (i) nuove cambiali per un totale di 11,1 milioni di dollari e (ii) 325.651 azioni di nuova emissione della Serie Y Preferred Convertible valutate a 19,96 dollari per azione. Ogni azione preferenziale si converte in 9,0909 azioni ordinarie, implicando un’emissione potenziale di circa 3,0 milioni di azioni ordinarie aggiuntive una volta rimossi i limiti di conversione.

L’operazione riduce immediatamente il capitale del debito di circa 5,9 milioni di dollari, sposta una parte dell’esposizione del finanziatore in capitale proprio e non richiede registrazione ai sensi della Sezione 3(a)(9). Un Terzo Accordo Emendato e Rifirmato sui Diritti di Registrazione obbliga la Società a presentare una registrazione a scaffale per le azioni di conversione entro 60 giorni dalla conversione di tutte le azioni preferenziali.

Parallelamente, la Società e Madryn hanno firmato diversi accordi di consenso e modifica: (1) rinuncia ai covenant di liquidità minima sia per il Main Street Priority Loan che per le nuove cambiali fino al 31 luglio 2025, (2) autorizzazione ad applicare il pagamento degli interessi del 8 luglio 2025 al capitale, e (3) una diciassettesima modifica al Bridge Loan che estende la scadenza di un mese fino al 31 luglio 2025.

Per supportare l’emissione maggiore delle azioni preferenziali, Venus ha depositato un Certificato di Modifica che aumenta le azioni autorizzate della Serie Y da 1,2 milioni a 1,5 milioni. Sarà richiesto un voto degli azionisti per rimuovere i limiti di conversione legati al Nasdaq.

In sintesi, il pacchetto offre un sollievo temporaneo dai covenant e una modesta riduzione del debito, ma comporta una potenziale diluizione azionaria e mette in evidenza le persistenti restrizioni di liquidità, con diverse scadenze chiave ora posticipate solo a fine luglio 2025.

Venus Concept Inc. (NASDAQ: VERO) ha completado una serie de enmiendas financieras relacionadas diseñadas para aliviar la presión de liquidez a corto plazo y realinear su estructura de capital.

El 30 de junio de 2025, la Compañía ejecutó un Acuerdo de Intercambio con su prestamista principal Madryn Health Partners. Dos pagarés convertibles subordinados garantizados existentes, con un principal agregado de 17,0 millones de dólares, fueron intercambiados por (i) nuevos pagarés por un total de 11,1 millones de dólares y (ii) 325,651 acciones recién emitidas de la Serie Y Convertible Preferred Stock valoradas en 19,96 dólares por acción. Cada acción preferente se convierte en 9,0909 acciones ordinarias, lo que implica una emisión potencial de aproximadamente 3,0 millones de acciones ordinarias adicionales una vez que se levanten los límites de conversión.

La transacción reduce inmediatamente el principal de la deuda en aproximadamente 5,9 millones de dólares, convierte una parte de la exposición del prestamista en capital y no requiere registro bajo la Sección 3(a)(9). Un Tercer Acuerdo Enmendado y Restablecido de Derechos de Registro obliga a la Compañía a presentar un registro en estantería para las acciones de conversión dentro de los 60 días posteriores a la conversión de todas las acciones preferentes.

Simultáneamente, la Compañía y Madryn ejecutaron varios acuerdos de consentimiento y enmienda: (1) renuncia a los convenios de liquidez mínima tanto en el Préstamo Prioritario Main Street como en los nuevos pagarés hasta el 31 de julio de 2025, (2) permiso para aplicar el pago de intereses del 8 de julio de 2025 al principal, y (3) una decimosexta enmienda al Préstamo Puente que extiende el vencimiento un mes hasta el 31 de julio de 2025.

Para apoyar la mayor emisión preferente, Venus presentó un Certificado de Enmienda que incrementa las acciones autorizadas de la Serie Y de 1,2 millones a 1,5 millones. Se buscará una votación de accionistas para eliminar los límites de conversión relacionados con Nasdaq.

En conjunto, el paquete proporciona alivio temporal de convenios y una reducción modesta de la deuda, pero añade una posible dilución de capital y destaca las continuas restricciones de liquidez, con varios vencimientos clave ahora aplazados solo hasta finales de julio de 2025.

Venus Concept Inc. (NASDAQ: VERO)는 단기 유동성 압박을 완화하고 자본 구조를 재조정하기 위해 일련의 관련 금융 수정 사항을 완료했습니다.

2025년 6월 30일, 회사는 주요 대출기관인 Madryn Health Partners와 교환 계약을 체결했습니다. 총 원금 1,700만 달러의 기존 담보 하위 전환사채 두 건이 (i) 총 1,110만 달러의 새로운 약속어음과 (ii) 주당 19.96달러로 평가된 신규 발행된 시리즈 Y 전환 우선주 325,651주로 교환되었습니다. 각 우선주는 9.0909주의 보통주로 전환되며, 전환 제한이 해제되면 약 300만 주의 추가 보통주가 발행될 수 있습니다.

이번 거래로 부채 원금이 약 590만 달러 감소하고, 대출자의 일부 노출이 주식으로 전환되며, 섹션 3(a)(9)에 따른 등록 요건이 없습니다. 제3차 수정 및 재작성된 등록 권리 계약에 따라 회사는 모든 우선주가 전환된 후 60일 이내에 전환주에 대한 선반 등록을 제출해야 합니다.

동시에 회사와 Madryn은 여러 동의 및 수정 계약을 체결했습니다: (1) 2025년 7월 31일까지 Main Street 우선 대출과 신규 약속어음에 대한 최소 유동성 계약 위반 면제, (2) 2025년 7월 8일 이자 지급액을 원금에 적용하는 허가, (3) 만기를 한 달 연장하여 2025년 7월 31일까지 연장하는 16차 브리지 론 수정.

더 큰 우선주 발행을 지원하기 위해 Venus는 시리즈 Y 승인 주식 수를 120만 주에서 150만 주로 증가하는 수정 증명서를 제출했습니다. Nasdaq 관련 전환 제한을 해제하기 위한 주주 투표가 진행될 예정입니다.

전반적으로 이 패키지는 단기 계약 완화와 적당한 부채 감축을 제공하지만, 잠재적인 주식 희석을 추가하며 지속되는 유동성 제약을 강조합니다. 여러 주요 만기가 이제 2025년 7월 말로 연기되었습니다.

Venus Concept Inc. (NASDAQ : VERO) a finalisé une série d'amendements financiers liés visant à alléger la pression sur la liquidité à court terme et à réaligner sa structure de capital.

Le 30 juin 2025, la Société a conclu un Contrat d'Échange avec son prêteur principal Madryn Health Partners. Deux billets convertibles subordonnés garantis existants, d'un principal total de 17,0 millions de dollars, ont été échangés contre (i) de nouveaux billets à ordre totalisant 11,1 millions de dollars et (ii) 325 651 actions nouvellement émises de Série Y Preferred Convertible au prix de 19,96 dollars par action. Chaque action privilégiée se convertit en 9,0909 actions ordinaires, ce qui implique une émission potentielle d'environ 3,0 millions d'actions ordinaires supplémentaires une fois les limites de conversion levées.

La transaction réduit immédiatement le principal de la dette d'environ 5,9 millions de dollars, convertit une partie de l'exposition du prêteur en capitaux propres et ne nécessite pas d'enregistrement en vertu de la Section 3(a)(9). Un troisième accord modifié et restitué sur les droits d'enregistrement oblige la Société à déposer un enregistrement en étagère pour les actions de conversion dans les 60 jours suivant la conversion de toutes les actions privilégiées.

Parallèlement, la Société et Madryn ont conclu plusieurs accords de consentement et d'amendement : (1) renonciation aux engagements de liquidité minimale sur le prêt prioritaire Main Street et les nouveaux billets jusqu'au 31 juillet 2025, (2) autorisation d'appliquer le paiement des intérêts du 8 juillet 2025 au principal, et (3) une seizième modification du prêt relais prolongeant l'échéance d'un mois jusqu'au 31 juillet 2025.

Pour soutenir la plus grande émission d'actions privilégiées, Venus a déposé un certificat de modification augmentant les actions autorisées de la Série Y de 1,2 million à 1,5 million. Un vote des actionnaires sera sollicité pour supprimer les limites de conversion liées au Nasdaq.

Dans l'ensemble, ce paquet offre un allégement temporaire des engagements et une réduction modeste de la dette, mais entraîne une dilution potentielle des actions et souligne les contraintes de liquidité persistantes, plusieurs échéances clés étant désormais reportées à fin juillet 2025.

Venus Concept Inc. (NASDAQ: VERO) hat eine Reihe von damit verbundenen Finanzierungsänderungen abgeschlossen, die darauf abzielen, den kurzfristigen Liquiditätsdruck zu verringern und die Kapitalstruktur neu auszurichten.

Am 30. Juni 2025 schloss das Unternehmen eine Tauschvereinbarung mit seinem Hauptkreditgeber Madryn Health Partners ab. Zwei bestehende besicherte nachrangige wandelbare Schuldverschreibungen mit einem Gesamtnennwert von 17,0 Millionen US-Dollar wurden gegen (i) neue Schuldscheine mit einem Gesamtwert von 11,1 Millionen US-Dollar und (ii) 325.651 neu ausgegebene Aktien der Serie Y Wandelvorzugsaktien zum Preis von 19,96 US-Dollar pro Aktie getauscht. Jede Vorzugsaktie wandelt sich in 9,0909 Stammaktien um, was eine potenzielle Ausgabe von etwa 3,0 Millionen zusätzlichen Stammaktien impliziert, sobald die Umwandlungsbeschränkungen aufgehoben sind.

Die Transaktion reduziert sofort den Schuldenkapitalbetrag um etwa 5,9 Millionen US-Dollar, verlagert einen Teil der Kreditgeberexposition in Eigenkapital und unterliegt keiner Registrierungspflicht gemäß Abschnitt 3(a)(9). Ein drittes geändertes und neu gefasstes Registrierungsrechtsabkommen verpflichtet das Unternehmen, innerhalb von 60 Tagen nach Umwandlung aller Vorzugsaktien eine Shelf-Registrierung für die Umwandlungsaktien einzureichen.

Gleichzeitig schlossen das Unternehmen und Madryn mehrere Zustimmungs- und Änderungsvereinbarungen ab: (1) Verzicht auf Mindestliquiditätsklauseln sowohl für den Main Street Priority Loan als auch für die neuen Schuldscheine bis zum 31. Juli 2025, (2) Erlaubnis, die Zinszahlung am 8. Juli 2025 auf das Kapital anzurechnen, und (3) eine sechzehnte Änderung des Bridge Loans, die die Fälligkeit um einen Monat bis zum 31. Juli 2025 verlängert.

Zur Unterstützung der größeren Vorzugsausgabe reichte Venus eine Änderungsurkunde ein, die die genehmigten Aktien der Serie Y von 1,2 Millionen auf 1,5 Millionen erhöht. Eine Aktionärsabstimmung wird angestrebt, um die Nasdaq-bezogenen Umwandlungsbeschränkungen aufzuheben.

Insgesamt bietet das Paket kurzfristige Erleichterungen bei den Auflagen und eine moderate Schuldenreduzierung, führt jedoch zu potenzieller Aktienverwässerung und unterstreicht anhaltende Liquiditätsengpässe, wobei mehrere wichtige Fälligkeiten nun erst Ende Juli 2025 anstehen.

 

   

Registration Statement No. 333-275898

Filed Pursuant to Rule 424(b)(2)

The information in this preliminary pricing supplement is not complete and may be changed.

     

Preliminary Pricing Supplement

Subject to Completion: Dated July 1, 2025

 

Pricing Supplement dated July __, 2025 to the Prospectus dated December 20, 2023, the Prospectus Supplement dated December 20, 2023 and the Product Supplement No. 1A dated May 16, 2024

 

$
Capped Enhanced Return Buffer Notes
Linked to the Common Stock of NVIDIA Corporation,
Due January 20, 2027

 

Royal Bank of Canada

 

     

 

Royal Bank of Canada is offering Capped Enhanced Return Buffer Notes (the “Notes”) linked to the performance of the common stock of NVIDIA Corporation (the “Underlier”).

·Capped Enhanced Return Potential — If the Final Underlier Value is greater than the Initial Underlier Value, at maturity, investors will receive a return equal to 150% of the Underlier Return, subject to the Maximum Return of 36.80%.

·Contingent Return of Principal at Maturity — If the Final Underlier Value is less than or equal to the Initial Underlier Value, but is greater than or equal to the Buffer Value (80% of the Initial Underlier Value), at maturity, investors will receive the principal amount of their Notes. If the Final Underlier Value is less than the Buffer Value, at maturity, investors will lose 1% of the principal amount of their Notes for each 1% that the Final Underlier Value is less than the Initial Underlier Value in excess of the Buffer Percentage of 20%.

·The Notes do not pay interest.

·Any payments on the Notes are subject to our credit risk.

·The Notes will not be listed on any securities exchange.

CUSIP: 78017PDL2

Investing in the Notes involves a number of risks. See “Selected Risk Considerations” beginning on page P-6 of this pricing supplement and “Risk Factors” in the accompanying prospectus, prospectus supplement and product supplement.

None of the Securities and Exchange Commission (the “SEC”), any state securities commission or any other regulatory body has approved or disapproved of the Notes or passed upon the adequacy or accuracy of this pricing supplement. Any representation to the contrary is a criminal offense. The Notes will not constitute deposits insured by the Canada Deposit Insurance Corporation, the U.S. Federal Deposit Insurance Corporation or any other Canadian or U.S. governmental agency or instrumentality. The Notes are not bail-inable notes and are not subject to conversion into our common shares under subsection 39.2(2.3) of the Canada Deposit Insurance Corporation Act.

 

Per Note

 

Total

Price to public(1) 100.00%   $
Underwriting discounts and commissions(1)

1.00%

 

$

Proceeds to Royal Bank of Canada 99.00%   $

(1) We or one of our affiliates may pay varying selling concessions of up to $10.00 per $1,000 principal amount of Notes in connection with the distribution of the Notes to other registered broker-dealers. Certain dealers who purchase the Notes for sale to certain fee-based advisory accounts may forgo some or all of their underwriting discount or selling concessions. The public offering price for investors purchasing the Notes in these accounts may be between $990.00 and $1,000.00 per $1,000 principal amount of Notes. In addition, we or one of our affiliates may pay a broker-dealer that is not affiliated with us a referral fee of up to $6.75 per $1,000 principal amount of Notes. See “Supplemental Plan of Distribution (Conflicts of Interest)” below.

The initial estimated value of the Notes determined by us as of the Trade Date, which we refer to as the initial estimated value, is expected to be between $935.00 and $985.00 per $1,000 principal amount of Notes and will be less than the public offering price of the Notes. The final pricing supplement relating to the Notes will set forth the initial estimated value. The market value of the Notes at any time will reflect many factors, cannot be predicted with accuracy and may be less than this amount. We describe the determination of the initial estimated value in more detail below.

 

RBC Capital Markets, LLC

  
 

Capped Enhanced Return Buffer Notes Linked to the Common Stock of NVIDIA Corporation

KEY TERMS

 

The information in this “Key Terms” section is qualified by any more detailed information set forth in this pricing supplement and in the accompanying prospectus, prospectus supplement and product supplement.

 

Issuer: Royal Bank of Canada
Underwriter: RBC Capital Markets, LLC (“RBCCM”)
Minimum Investment: $1,000 and minimum denominations of $1,000 in excess thereof
Underlier: The common stock of NVIDIA Corporation
  Bloomberg Ticker Initial Underlier Value(1) Buffer Value(2)
  NVDA UW $ $
  (1) The closing value of the Underlier on the Trade Date
  (2) 80% of the Initial Underlier Value (rounded to two decimal places)
Trade Date: July 14, 2025
Issue Date: July 17, 2025
Valuation Date:* January 14, 2027
Maturity Date:* January 20, 2027
Payment at Maturity:

Investors will receive on the Maturity Date per $1,000 principal amount of Notes:

·     If the Final Underlier Value is greater than the Initial Underlier Value, an amount equal to:

$1,000 + ($1,000 × the lesser of (a) Underlier Return × Participation Rate and (b) Maximum Return) 

·     If the Final Underlier Value is less than or equal to the Initial Underlier Value, but is greater than or equal to the Buffer Value: $1,000

·     If the Final Underlier Value is less than the Buffer Value, an amount equal to:

$1,000 + [$1,000 × (Underlier Return + Buffer Percentage)] 

If the Final Underlier Value is less than the Buffer Value, you will lose some or a substantial portion of your principal amount at maturity. All payments on the Notes are subject to our credit risk.

Participation Rate: 150% (subject to the Maximum Return)
Maximum Return: 36.80%. Accordingly, the maximum payment at maturity will be $1,368 per $1,000 principal amount of Notes.
Buffer Percentage: 20%
Underlier Return:

The Underlier Return, expressed as a percentage, is calculated using the following formula:

Final Underlier Value – Initial Underlier Value
Initial Underlier Value 

Final Underlier Value: The closing value of the Underlier on the Valuation Date
Calculation Agent: RBCCM

* Subject to postponement. See “General Terms of the Notes—Postponement of a Determination Date” and “General Terms of the Notes—Postponement of a Payment Date” in the accompanying product supplement.

 

P-2RBC Capital Markets, LLC
  
 

Capped Enhanced Return Buffer Notes Linked to the Common Stock of NVIDIA Corporation

ADDITIONAL TERMS OF YOUR NOTES

 

You should read this pricing supplement together with the prospectus dated December 20, 2023, as supplemented by the prospectus supplement dated December 20, 2023, relating to our Senior Global Medium-Term Notes, Series J, of which the Notes are a part, and the product supplement no. 1A dated May 16, 2024. This pricing supplement, together with these documents, contains the terms of the Notes and supersedes all other prior or contemporaneous oral statements as well as any other written materials, including preliminary or indicative pricing terms, correspondence, trade ideas, structures for implementation, sample structures, fact sheets, brochures or other educational materials of ours.

 

We have not authorized anyone to provide any information or to make any representations other than those contained or incorporated by reference in this pricing supplement and the documents listed below. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. These documents are an offer to sell only the Notes offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in each such document is current only as of its date.

 

If the information in this pricing supplement differs from the information contained in the documents listed below, you should rely on the information in this pricing supplement.

 

You should carefully consider, among other things, the matters set forth in “Selected Risk Considerations” in this pricing supplement and “Risk Factors” in the documents listed below, as the Notes involve risks not associated with conventional debt securities. We urge you to consult your investment, legal, tax, accounting and other advisers before you invest in the Notes.

 

You may access these documents on the SEC website at www.sec.gov as follows (or if such address has changed, by reviewing our filings for the relevant date on the SEC website):

 

·Prospectus dated December 20, 2023:

https://www.sec.gov/Archives/edgar/data/1000275/000119312523299520/d645671d424b3.htm

 

·Prospectus Supplement dated December 20, 2023:

https://www.sec.gov/Archives/edgar/data/1000275/000119312523299523/d638227d424b3.htm

 

·Product Supplement No. 1A dated May 16, 2024:

https://www.sec.gov/Archives/edgar/data/1000275/000095010324006777/dp211286_424b2-ps1a.htm

 

Our Central Index Key, or CIK, on the SEC website is 1000275. As used in this pricing supplement, “Royal Bank of Canada,” the “Bank,” “we,” “our” and “us” mean only Royal Bank of Canada.

 

P-3RBC Capital Markets, LLC
  
 

Capped Enhanced Return Buffer Notes Linked to the Common Stock of NVIDIA Corporation

HYPOTHETICAL RETURNS

 

The table and examples set forth below illustrate hypothetical payments at maturity for hypothetical performance of the Underlier, based on the Buffer Value of 80% of the Initial Underlier Value, the Participation Rate of 150%, the Maximum Return of 36.80% and the Buffer Percentage of 20%. The table and examples are only for illustrative purposes and may not show the actual return applicable to investors.

 

Hypothetical Underlier Return Payment at Maturity per $1,000 Principal Amount of Notes Payment at Maturity as Percentage of Principal Amount
50.0000% $1,368.00 136.800%
40.0000% $1,368.00 136.800%
30.0000% $1,368.00 136.800%
24.5334% $1,368.00 136.800%
20.0000% $1,300.00 130.000%
10.0000% $1,150.00 115.000%
5.0000% $1,075.00 107.500%
2.0000% $1,030.00 103.000%
0.0000% $1,000.00 100.000%
-5.0000% $1,000.00 100.000%
-10.0000% $1,000.00 100.000%
-20.0000% $1,000.00 100.000%
-30.0000% $900.00 90.000%
-40.0000% $800.00 80.000%
-50.0000% $700.00 70.000%
-60.0000% $600.00 60.000%
-70.0000% $500.00 50.000%
-80.0000% $400.00 40.000%
-90.0000% $300.00 30.000%
-100.0000% $200.00 20.000%

 

Example 1 —   The value of the Underlier increases from the Initial Underlier Value to the Final Underlier Value by 2%.
  Underlier Return: 2%
  Payment at Maturity:

$1,000 + ($1,000 × the lesser of (a) 2% × 150% and (b) 36.80%)

= $1,000 + ($1,000 × the lesser of (a) 3% and (b) 36.80%)

= $1,000 + ($1,000 × 3%) = $1,000 + $30 = $1,030

 

In this example, the payment at maturity is $1,030 per $1,000 principal amount of Notes, for a return of 3%.

Because the Final Underlier Value is greater than the Initial Underlier Value, investors receive a return equal to 150% of the Underlier Return, subject to the Maximum Return of 36.80%.

   
P-4RBC Capital Markets, LLC
  
 

Capped Enhanced Return Buffer Notes Linked to the Common Stock of NVIDIA Corporation

Example 2 — The value of the Underlier increases from the Initial Underlier Value to the Final Underlier Value by 40%, resulting in a return equal to the Maximum Return.
  Underlier Return: 40%
  Payment at Maturity:

$1,000 + ($1,000 × the lesser of (a) 40% × 150% and (b) 36.80%)

= $1,000 + ($1,000 × the lesser of (a) 60% and (b) 36.80%)

= $1,000 + ($1,000 × 36.80%) = $1,000 + $368 = $1,368

 

In this example, the payment at maturity is $1,368 per $1,000 principal amount of Notes, for a return of 36.80%, which is the Maximum Return.

This example illustrates that investors will not receive a return at maturity in excess of the Maximum Return. Accordingly, the return on the Notes may be less than the return of the Underlier.

   
Example 3 — The value of the Underlier decreases from the Initial Underlier Value to the Final Underlier Value by 10% (i.e., the Final Underlier Value is below the Initial Underlier Value but above the Buffer Value).
  Underlier Return: -10%
  Payment at Maturity: $1,000
 

In this example, the payment at maturity is $1,000 per $1,000 principal amount of Notes, for a return of 0%.

Because the Final Underlier Value is greater than the Buffer Value, investors receive a full return of the principal amount of their Notes.

   
Example 4 —   The value of the Underlier decreases from the Initial Underlier Value to the Final Underlier Value by 50% (i.e., the Final Underlier Value is below the Buffer Value).
  Underlier Return: -50%
  Payment at Maturity: $1,000 + [$1,000 × (-50% + 20%)] = $1,000 – $300 = $700
 

In this example, the payment at maturity is $700 per $1,000 principal amount of Notes, representing a loss of 30% of the principal amount.

Because the Final Underlier Value is less than the Buffer Value, investors do not receive a full return of the principal amount of their Notes.

   

Investors in the Notes could lose some or a substantial portion of the principal amount of their Notes at maturity.

 


P-5RBC Capital Markets, LLC
  
 

Capped Enhanced Return Buffer Notes Linked to the Common Stock of NVIDIA Corporation

SELECTED RISK CONSIDERATIONS

 

An investment in the Notes involves significant risks. We urge you to consult your investment, legal, tax, accounting and other advisers before you invest in the Notes. Some of the risks that apply to an investment in the Notes are summarized below, but we urge you to read also the “Risk Factors” sections of the accompanying prospectus, prospectus supplement and product supplement. You should not purchase the Notes unless you understand and can bear the risks of investing in the Notes.

 

Risks Relating to the Terms and Structure of the Notes

 

·You May Lose a Substantial Portion of the Principal Amount at Maturity — If the Final Underlier Value is less than the Buffer Value, you will lose 1% of the principal amount of your Notes for each 1% that the Final Underlier Value is less than the Initial Underlier Value in excess of the Buffer Percentage. You could lose some or a substantial portion of your principal amount at maturity.

 

·Your Potential Return at Maturity Is Limited — Your return on the Notes will not exceed the Maximum Return, regardless of any appreciation in the value of the Underlier, which may be significant. Accordingly, your return on the Notes may be less than your return would be if you made an investment in a security directly linked to the positive performance of the Underlier.

 

·The Notes Do Not Pay Interest, and Your Return on the Notes May Be Lower Than the Return on a Conventional Debt Security of Comparable Maturity — There will be no periodic interest payments on the Notes as there would be on a conventional fixed-rate or floating-rate debt security having the same maturity. The return that you will receive on the Notes, which could be negative, may be less than the return you could earn on other investments. Even if your return is positive, your return may be less than the return you would earn if you purchased one of our conventional senior interest-bearing debt securities.

 

·Payments on the Notes Are Subject to Our Credit Risk, and Market Perceptions about Our Creditworthiness May Adversely Affect the Market Value of the Notes — The Notes are our senior unsecured debt securities, and your receipt of any amounts due on the Notes is dependent upon our ability to pay our obligations as they come due. If we were to default on our payment obligations, you may not receive any amounts owed to you under the Notes and you could lose your entire investment. In addition, any negative changes in market perceptions about our creditworthiness may adversely affect the market value of the Notes.

 

·Any Payment on the Notes Will Be Determined Based on the Closing Values of the Underlier on the Dates Specified — Any payment on the Notes will be determined based on the closing values of the Underlier on the dates specified. You will not benefit from any more favorable value of the Underlier determined at any other time.

 

·The U.S. Federal Income Tax Consequences of an Investment in the Notes Are Uncertain — There is no direct legal authority regarding the proper U.S. federal income tax treatment of the Notes, and significant aspects of the tax treatment of the Notes are uncertain. You should review carefully the section entitled “United States Federal Income Tax Considerations” herein, in combination with the section entitled “United States Federal Income Tax Considerations” in the accompanying product supplement, and consult your tax adviser regarding the U.S. federal income tax consequences of an investment in the Notes.

 

Risks Relating to the Initial Estimated Value of the Notes and the Secondary Market for the Notes

 

·There May Not Be an Active Trading Market for the Notes; Sales in the Secondary Market May Result in Significant Losses — There may be little or no secondary market for the Notes. The Notes will not be listed on any securities exchange. RBCCM and our other affiliates may make a market for the Notes; however, they are not required to do so and, if they choose to do so, may stop any market-making activities at any time. Because other dealers are not likely to make a secondary market for the Notes, the price at which you may be able to trade your Notes is likely to depend on the price, if any, at which RBCCM or any of our other affiliates is willing to buy the Notes. Even if a secondary market for the Notes develops, it may not provide enough liquidity to allow you to easily trade or sell the Notes. We

 

P-6RBC Capital Markets, LLC
  
 

Capped Enhanced Return Buffer Notes Linked to the Common Stock of NVIDIA Corporation

expect that transaction costs in any secondary market would be high. As a result, the difference between bid and ask prices for your Notes in any secondary market could be substantial. If you sell your Notes before maturity, you may have to do so at a substantial discount from the price that you paid for them, and as a result, you may suffer significant losses. The Notes are not designed to be short-term trading instruments. Accordingly, you should be able and willing to hold your Notes to maturity.

 

·The Initial Estimated Value of the Notes Will Be Less Than the Public Offering Price — The initial estimated value of the Notes will be less than the public offering price of the Notes and does not represent a minimum price at which we, RBCCM or any of our other affiliates would be willing to purchase the Notes in any secondary market (if any exists) at any time. If you attempt to sell the Notes prior to maturity, their market value may be lower than the price you paid for them and the initial estimated value. This is due to, among other things, changes in the value of the Underlier, the internal funding rate we pay to issue securities of this kind (which is lower than the rate at which we borrow funds by issuing conventional fixed rate debt) and the inclusion in the public offering price of the underwriting discount, the referral fee, our estimated profit and the estimated costs relating to our hedging of the Notes. These factors, together with various credit, market and economic factors over the term of the Notes, are expected to reduce the price at which you may be able to sell the Notes in any secondary market and will affect the value of the Notes in complex and unpredictable ways. Assuming no change in market conditions or any other relevant factors, the price, if any, at which you may be able to sell your Notes prior to maturity may be less than your original purchase price, as any such sale price would not be expected to include the underwriting discount, the referral fee, our estimated profit or the hedging costs relating to the Notes. In addition, any price at which you may sell the Notes is likely to reflect customary bid-ask spreads for similar trades. In addition to bid-ask spreads, the value of the Notes determined for any secondary market price is expected to be based on a secondary market rate rather than the internal funding rate used to price the Notes and determine the initial estimated value. As a result, the secondary market price will be less than if the internal funding rate were used.

 

·The Initial Estimated Value of the Notes Is Only an Estimate, Calculated as of the Trade Date — The initial estimated value of the Notes is based on the value of our obligation to make the payments on the Notes, together with the mid-market value of the derivative embedded in the terms of the Notes. See “Structuring the Notes” below. Our estimate is based on a variety of assumptions, including our internal funding rate (which represents a discount from our credit spreads), expectations as to dividends, interest rates and volatility and the expected term of the Notes. These assumptions are based on certain forecasts about future events, which may prove to be incorrect. Other entities may value the Notes or similar securities at a price that is significantly different than we do.

 

The value of the Notes at any time after the Trade Date will vary based on many factors, including changes in market conditions, and cannot be predicted with accuracy. As a result, the actual value you would receive if you sold the Notes in any secondary market, if any, should be expected to differ materially from the initial estimated value of the Notes.

 

Risks Relating to Conflicts of Interest and Our Trading Activities

 

·Our and Our Affiliates’ Business and Trading Activities May Create Conflicts of Interest — You should make your own independent investigation of the merits of investing in the Notes. Our and our affiliates’ economic interests are potentially adverse to your interests as an investor in the Notes due to our and our affiliates’ business and trading activities, and we and our affiliates have no obligation to consider your interests in taking any actions that might affect the value of the Notes. Trading by us and our affiliates may adversely affect the value of the Underlier and the market value of the Notes. See “Risk Factors—Risks Relating to Conflicts of Interest” in the accompanying product supplement.

 

·RBCCM’s Role as Calculation Agent May Create Conflicts of Interest — As Calculation Agent, our affiliate, RBCCM, will determine any values of the Underlier and make any other determinations necessary to calculate any payments on the Notes. In making these determinations, the Calculation Agent may be required to make discretionary judgments, including those described under “—Risks Relating to the Underlier” below. In making these discretionary judgments, the economic interests of the Calculation Agent are potentially adverse to your interests as an investor in the Notes, and any of these determinations may adversely affect any payments on the Notes. The Calculation Agent will have no obligation to consider your interests as an investor in the Notes in making any determinations with respect to the Notes.

 

P-7RBC Capital Markets, LLC
  
 

Capped Enhanced Return Buffer Notes Linked to the Common Stock of NVIDIA Corporation

Risks Relating to the Underlier

 

·You Will Not Have Any Rights to the Underlier — As an investor in the Notes, you will not have voting rights or rights to receive dividends or other distributions or any other rights with respect to the Underlier.

 

·Any Payment on the Notes May Be Postponed and Adversely Affected by the Occurrence of a Market Disruption Event — The timing and amount of any payment on the Notes is subject to adjustment upon the occurrence of a market disruption event affecting the Underlier. If a market disruption event persists for a sustained period, the Calculation Agent may make a discretionary determination of the closing value of the Underlier. See “General Terms of the Notes—Reference Stocks and Funds—Market Disruption Events,” “General Terms of the Notes—Postponement of a Determination Date” and “General Terms of the Notes—Postponement of a Payment Date” in the accompanying product supplement.

 

·Anti-dilution Protection Is Limited, and the Calculation Agent Has Discretion to Make Anti-dilution Adjustments — The Calculation Agent may in its sole discretion make adjustments affecting any amounts payable on the Notes upon the occurrence of certain corporate events (such as stock splits or extraordinary or special dividends) that the Calculation Agent determines have a diluting or concentrative effect on the theoretical value of the Underlier. However, the Calculation Agent might not make adjustments in response to all such events that could affect the Underlier. The occurrence of any such event and any adjustment made by the Calculation Agent (or a determination by the Calculation Agent not to make any adjustment) may adversely affect the market price of, and any amounts payable on, the Notes. See “General Terms of the Notes—Reference Stocks and Funds—Anti-dilution Adjustments” in the accompanying product supplement.

 

·Reorganization or Other Events Could Adversely Affect the Value of the Notes or Result in the Notes Being Accelerated — Upon the occurrence of certain reorganization or other events affecting the Underlier, the Calculation Agent may make adjustments that result in payments on the Notes being based on the performance of (i) cash, securities of another issuer and/or other property distributed to holders of the Underlier upon the occurrence of that event or (ii) in the case of a reorganization event in which only cash is distributed to holders of the Underlier, a substitute security, if the Calculation Agent elects to select one. Any of these actions could adversely affect the value of the Underlier and, consequently, the value of the Notes. Alternatively, the Calculation Agent may accelerate the Maturity Date for a payment determined by the Calculation Agent. Any amount payable upon acceleration could be significantly less than any amount that would be due on the Notes if they were not accelerated. However, if the Calculation Agent elects not to accelerate the Notes, the value of, and any amount payable on, the Notes could be adversely affected, perhaps significantly. See “General Terms of the Notes—Reference Stocks and Funds—Anti-dilution Adjustments—Reorganization Events” in the accompanying product supplement.

 

P-8RBC Capital Markets, LLC
  
 

Capped Enhanced Return Buffer Notes Linked to the Common Stock of NVIDIA Corporation

INFORMATION REGARDING THE UNDERLIER

 

The Underlier is registered under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Companies with securities registered under the Exchange Act are required to file financial and other information specified by the SEC periodically. Information provided to or filed with the SEC by the issuer of the Underlier can be located on a website maintained by the SEC at https://www.sec.gov by reference to that issuer’s SEC file number provided below. Information from outside sources is not incorporated by reference in, and should not be considered part of, this pricing supplement. We have not independently verified the accuracy or completeness of the information contained in outside sources.

 

According to publicly available information, NVIDIA Corporation is a full-stack computing infrastructure company with data-center-scale offerings whose full-stack includes the CUDA programming model that runs on all of its graphics processing units (GPUs), as well as domain-specific software libraries, software development kits and Application Programming Interfaces.

 

The issuer of the Underlier’s SEC file number is 000-23985. The Underlier is listed on The Nasdaq Stock Market under the ticker symbol “NVDA.”

 

Historical Information

 

The following graph sets forth historical closing values of the Underlier for the period from January 1, 2015 to June 30, 2025. The red line represents a hypothetical Buffer Value based on the closing value of the Underlier on June 30, 2025. We obtained the information in the graph from Bloomberg Financial Markets, without independent investigation. We cannot give you assurance that the performance of the Underlier will result in the return of all of your initial investment.

 

Common Stock of NVIDIA Corporation

 

 

PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS.

 

P-9RBC Capital Markets, LLC
  
 

Capped Enhanced Return Buffer Notes Linked to the Common Stock of NVIDIA Corporation

UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS

 

You should review carefully the section in the accompanying product supplement entitled “United States Federal Income Tax Considerations.” The following discussion, when read in combination with that section, constitutes the full opinion of our counsel, Davis Polk & Wardwell LLP, regarding the material U.S. federal income tax consequences of owning and disposing of the Notes.

 

Generally, this discussion assumes that you purchased the Notes for cash in the original issuance at the stated issue price and does not address other circumstances specific to you, including consequences that may arise due to any other investments relating to the Underlier. You should consult your tax adviser regarding the effect any such circumstances may have on the U.S. federal income tax consequences of your ownership of a Note.

 

In the opinion of our counsel, which is based on current market conditions, it is reasonable to treat the Notes for U.S. federal income tax purposes as prepaid financial contracts that are “open transactions,” as described in the section entitled “United States Federal Income Tax Considerations—Tax Consequences to U.S. Holders—Notes Treated as Prepaid Financial Contracts that are Open Transactions” in the accompanying product supplement. There is uncertainty regarding this treatment, and the Internal Revenue Service (the “IRS”) or a court might not agree with it. Moreover, because this treatment of the Notes and our counsel’s opinion are based on market conditions as of the date of this preliminary pricing supplement, each is subject to confirmation on the Trade Date. A different tax treatment could be adverse to you. Generally, if this treatment is respected, (i) you should not recognize taxable income or loss prior to the taxable disposition of your Notes (including upon maturity or an earlier redemption, if applicable) and (ii) the gain or loss on your Notes should be treated as short-term capital gain or loss unless you have held the Notes for more than one year, in which case your gain or loss should be treated as long-term capital gain or loss.

 

We do not plan to request a ruling from the IRS regarding the treatment of the Notes. An alternative characterization of the Notes could materially and adversely affect the tax consequences of ownership and disposition of the Notes, including the timing and character of income recognized. In addition, the U.S. Treasury Department and the IRS have requested comments on various issues regarding the U.S. federal income tax treatment of “prepaid forward contracts” and similar financial instruments and have indicated that such transactions may be the subject of future regulations or other guidance. Furthermore, members of Congress have proposed legislative changes to the tax treatment of derivative contracts. Any legislation, Treasury regulations or other guidance promulgated after consideration of these issues could materially and adversely affect the tax consequences of an investment in the Notes, possibly with retroactive effect.

 

Non-U.S. Holders. As discussed under “United States Federal Income Tax Considerations—Tax Consequences to Non-U.S. Holders—Dividend Equivalents under Section 871(m) of the Code” in the accompanying product supplement, Section 871(m) of the Internal Revenue Code and Treasury regulations promulgated thereunder (“Section 871(m)”) generally impose a 30% withholding tax on dividend equivalents paid or deemed paid to Non-U.S. Holders with respect to certain financial instruments linked to U.S. equities or indices that include U.S. equities. The Treasury regulations, as modified by an IRS notice, exempt financial instruments issued prior to January 1, 2027 that do not have a “delta” of one. Based on certain determinations made by us, we expect that Section 871(m) will not apply to the Notes with regard to Non-U.S. Holders. Our determination is not binding on the IRS, and the IRS may disagree with this determination. If necessary, further information regarding the potential application of Section 871(m) will be provided in the final pricing supplement for the Notes.

 

We will not be required to pay any additional amounts with respect to U.S. federal withholding taxes.

 

You should consult your tax adviser regarding the U.S. federal income tax consequences of an investment in the Notes, including possible alternative treatments, as well as tax consequences arising under the laws of any state, local or non-U.S. taxing jurisdiction.

 

P-10RBC Capital Markets, LLC
  
 

Capped Enhanced Return Buffer Notes Linked to the Common Stock of NVIDIA Corporation

SUPPLEMENTAL PLAN OF DISTRIBUTION (CONFLICTS OF INTEREST)

 

The Notes are offered initially to investors at a purchase price equal to par, except with respect to certain accounts as indicated on the cover page of this pricing supplement. We or one of our affiliates may pay the underwriting discount and may pay a broker-dealer that is not affiliated with us a referral fee, in each case as set forth on the cover page of this pricing supplement.

 

The value of the Notes shown on your account statement may be based on RBCCM’s estimate of the value of the Notes if RBCCM or another of our affiliates were to make a market in the Notes (which it is not obligated to do). That estimate will be based on the price that RBCCM may pay for the Notes in light of then-prevailing market conditions, our creditworthiness and transaction costs. For a period of approximately three months after the Issue Date, the value of the Notes that may be shown on your account statement may be higher than RBCCM’s estimated value of the Notes at that time. This is because the estimated value of the Notes will not include the underwriting discount, the referral fee or our hedging costs and profits; however, the value of the Notes shown on your account statement during that period may initially be a higher amount, reflecting the addition of the underwriting discount, the referral fee and our estimated costs and profits from hedging the Notes. This excess is expected to decrease over time until the end of this period. After this period, if RBCCM repurchases your Notes, it expects to do so at prices that reflect their estimated value.

 

RBCCM or another of its affiliates or agents may use this pricing supplement in the initial sale of the Notes. In addition, RBCCM or another of our affiliates may use this pricing supplement in a market-making transaction in the Notes after their initial sale. Unless we or our agent informs the purchaser otherwise in the confirmation of sale, this pricing supplement is being used in a market-making transaction.

 

For additional information about the settlement cycle of the Notes, see “Plan of Distribution” in the accompanying prospectus. For additional information as to the relationship between us and RBCCM, see the section “Plan of Distribution—Conflicts of Interest” in the accompanying prospectus.

 

STRUCTURING THE NOTES

 

The Notes are our debt securities. As is the case for all of our debt securities, including our structured notes, the economic terms of the Notes reflect our actual or perceived creditworthiness. In addition, because structured notes result in increased operational, funding and liability management costs to us, we typically borrow the funds under structured notes at a rate that is lower than the rate that we might pay for a conventional fixed or floating rate debt security of comparable maturity. The lower internal funding rate, the underwriting discount, the referral fee and the hedging-related costs relating to the Notes reduce the economic terms of the Notes to you and result in the initial estimated value for the Notes being less than their public offering price. Unlike the initial estimated value, any value of the Notes determined for purposes of a secondary market transaction may be based on a secondary market rate, which may result in a lower value for the Notes than if our initial internal funding rate were used.

 

In order to satisfy our payment obligations under the Notes, we may choose to enter into certain hedging arrangements (which may include call options, put options or other derivatives) with RBCCM and/or one of our other subsidiaries. The terms of these hedging arrangements take into account a number of factors, including our creditworthiness, interest rate movements, volatility and the tenor of the Notes. The economic terms of the Notes and the initial estimated value depend in part on the terms of these hedging arrangements.

 

See “Selected Risk Considerations—Risks Relating to the Initial Estimated Value of the Notes and the Secondary Market for the Notes—The Initial Estimated Value of the Notes Will Be Less Than the Public Offering Price” above.

 

P-11RBC Capital Markets, LLC

FAQ

Why did Venus Concept (VERO) exchange its notes on 30 June 2025?

To lower debt principal, secure covenant waivers, and convert part of lender exposure into equity, thereby easing near-term liquidity pressure.

How much debt was reduced by the exchange?

Principal fell from $17.0 million to $11.1 million, a reduction of roughly $5.9 million.

What is the dilution impact of the new Series Y Preferred Stock?

The 325,651 preferred shares can convert into about 2.96 million common shares (9.0909 conversion ratio), pending shareholder approval.

How long are liquidity covenants waived under the new agreements?

Minimum liquidity requirements are waived through 31 July 2025 on the Main Street Loan and the new notes.

When does the amended bridge loan now mature?

The Sixteenth Bridge Loan Amendment extends the maturity date to 31 July 2025.

Will the conversion shares be registered?

The Company must file a shelf resale registration statement within 60 days after all preferred shares convert, per the amended registration rights agreement.
Royal Bk Can

NYSE:RY

RY Rankings

RY Latest News

RY Latest SEC Filings

RY Stock Data

183.58B
1.41B
0.01%
50.95%
0.46%
Banks - Diversified
Financial Services
Link
Canada
Toronto